X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3068) 3068
Magazine Article (21) 21
Book / eBook (11) 11
Web Resource (4) 4
Book Chapter (3) 3
Reference (2) 2
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
nootropic agents - therapeutic use (2425) 2425
humans (2396) 2396
male (1486) 1486
alzheimer disease - drug therapy (1053) 1053
animals (1052) 1052
female (1031) 1031
aged (944) 944
neurosciences (769) 769
nootropic agents - pharmacology (765) 765
pharmacology & pharmacy (701) 701
alzheimer's disease (695) 695
psychiatry (579) 579
dementia (569) 569
treatment outcome (569) 569
middle aged (545) 545
clinical neurology (540) 540
piperidines - therapeutic use (536) 536
indans - therapeutic use (529) 529
alzheimers-disease (491) 491
cholinesterase inhibitors - therapeutic use (477) 477
donepezil (454) 454
nootropic agents - adverse effects (449) 449
cognition - drug effects (445) 445
rats (434) 434
aged, 80 and over (399) 399
nootropic agents - administration & dosage (393) 393
double-blind (379) 379
cognition disorders - drug therapy (377) 377
memory (373) 373
neuropsychological tests (352) 352
adult (327) 327
mice (319) 319
disease models, animal (313) 313
cognition (309) 309
double-blind method (305) 305
neurology (290) 290
alzheimer disease - psychology (287) 287
brain (262) 262
geriatrics & gerontology (258) 258
brain - drug effects (253) 253
dose-response relationship, drug (251) 251
memory - drug effects (243) 243
dementia - drug therapy (237) 237
alzheimer disease - diagnosis (222) 222
neuroprotective agents - therapeutic use (217) 217
drug therapy (206) 206
galantamine - therapeutic use (202) 202
rivastigmine (200) 200
analysis (196) 196
efficacy (195) 195
time factors (193) 193
placebo-controlled trial (191) 191
randomized controlled trials as topic (186) 186
maze learning - drug effects (184) 184
clinical trials as topic (169) 169
alzheimers disease (168) 168
cognitive ability (168) 168
drug therapy, combination (166) 166
galantamine (166) 166
memory disorders - drug therapy (165) 165
rats, wistar (162) 162
memantine - therapeutic use (161) 161
cognition disorders - etiology (159) 159
severity of illness index (159) 159
piracetam - therapeutic use (156) 156
medicine, general & internal (150) 150
brain - metabolism (149) 149
clinical trials (146) 146
neurons - drug effects (146) 146
rats, sprague-dawley (146) 146
memantine (145) 145
hippocampus - drug effects (141) 141
disease progression (140) 140
research (139) 139
alzheimer disease - physiopathology (138) 138
behavior, animal - drug effects (135) 135
gerontology (133) 133
follow-up studies (131) 131
alzheimer disease - metabolism (130) 130
cholinesterase inhibitors (130) 130
schizophrenia (129) 129
cholinesterase inhibitors - adverse effects (128) 128
oxidative stress (127) 127
cytidine diphosphate choline - therapeutic use (124) 124
drugs (123) 123
hippocampus (122) 122
neurons - metabolism (122) 122
piperidines - adverse effects (122) 122
indans - adverse effects (118) 118
alzheimer’s disease (117) 117
adolescent (114) 114
health aspects (113) 113
care and treatment (112) 112
neuroprotective agents - pharmacology (109) 109
activities of daily living (108) 108
impairment (108) 108
pharmacology (107) 107
antipsychotic agents - therapeutic use (106) 106
medicine & public health (106) 106
biomedicine (103) 103
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2677) 2677
Russian (181) 181
German (113) 113
French (40) 40
Spanish (40) 40
Japanese (25) 25
Hungarian (15) 15
Chinese (13) 13
Italian (8) 8
Polish (6) 6
Ukrainian (6) 6
Dutch (4) 4
Finnish (3) 3
Czech (2) 2
Danish (2) 2
Portuguese (2) 2
Romanian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Psychiatry and clinical neurosciences, ISSN 1323-1316, 2015, Volume 69, Issue 6, pp. 321 - 334
Tardive dyskinesia is a serious, disabling and potentially permanent, neurological hyperkinetic movement disorder that occurs after months or years of taking... 
first‐generation agents | schizophrenia | management | second‐generation agents | tardive dyskinesia | second-generation agents | first-generation agents | VITAMIN-E TREATMENT | NEUROTROPHIC FACTOR LEVELS | SCHIZOPHRENIC-PATIENTS | PSYCHIATRY | GINKGO-BILOBA | CHAIN AMINO-ACIDS | NEUROSCIENCES | ATYPICAL ANTIPSYCHOTICS | CLINICAL NEUROLOGY | HYPERKINETIC MOVEMENT-DISORDERS | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | ESSENTIAL FATTY-ACIDS | Stilbenes - therapeutic use | Antipsychotic Agents - adverse effects | Humans | Propranolol - therapeutic use | Leucine - therapeutic use | Dopamine Agents - therapeutic use | Amantadine - therapeutic use | Piracetam - therapeutic use | Pyridoxine - therapeutic use | Clonazepam - therapeutic use | Drugs, Chinese Herbal - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Adrenergic Uptake Inhibitors - therapeutic use | Anticonvulsants - therapeutic use | Nootropic Agents - therapeutic use | Isoleucine - therapeutic use | Vitamins - therapeutic use | Ginkgo biloba | alpha-Tocopherol - therapeutic use | Antioxidants - therapeutic use | Movement Disorders - etiology | Piracetam - analogs & derivatives | Melatonin - therapeutic use | Fatty Acids, Omega-3 - therapeutic use | Valine - therapeutic use | Isoxazoles - therapeutic use | Plant Extracts - therapeutic use | Movement Disorders - drug therapy | Tetrabenazine - therapeutic use | Schizophrenia | Movement disorders | Tardive dyskinesia | Medical research
Journal Article
Biochemical pharmacology, ISSN 0006-2952, 2017, Volume 139, pp. 40 - 55
.... One common therapeutic strategy is to develop protein aggregation inhibitors that can slow down, prevent, or remodel toxic amyloids... 
Covalent mechanisms | Non-covalent mechanisms | Amyloid inhibitor | Natural products | Inhibition mechanisms | CLINICAL-TRIAL | PROTEIN AGGREGATION | ALZHEIMERS-DISEASE | SOLID DISPERSION | TEA POLYPHENOL (-)-EPIGALLOCATECHIN-3-GALLATE | ALPHA-SYNUCLEIN AGGREGATION | BETA-PEPTIDE AGGREGATION | A-BETA | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | AROMATIC-INHIBITOR | Amyloidosis - prevention & control | Drugs, Investigational - pharmacology | Antioxidants - chemistry | Nootropic Agents - metabolism | Antioxidants - metabolism | Healthy Diet | Humans | Polyphenols - pharmacology | Drugs, Investigational - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Biological Products - pharmacology | Flavonoids - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Polyphenols - metabolism | Amyloidogenic Proteins - antagonists & inhibitors | Drugs, Investigational - chemistry | Protein Aggregation, Pathological - prevention & control | Amyloidosis - diet therapy | Drug Design | Flavonoids - pharmacology | Protein Aggregation, Pathological - diet therapy | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Chelating Agents - therapeutic use | Biological Products - therapeutic use | Chelating Agents - chemistry | Nootropic Agents - therapeutic use | Amyloidosis - drug therapy | Antioxidants - pharmacology | Chelating Agents - pharmacology | Nootropic Agents - chemistry | Drug Discovery | Protein Aggregation, Pathological - drug therapy | Amyloidogenic Proteins - metabolism | Antioxidants - therapeutic use | Biological Products - chemistry | Animals | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Flavonoids - metabolism | Polyphenols - chemistry | Biological Products - metabolism | Polyphenols - therapeutic use | Chelating Agents - metabolism | Dietary Supplements | Flavonoids - chemistry | Amyloidosis - metabolism | Nootropic Agents - pharmacology | Medicine, Experimental | Medical research | Nervous system diseases | Glycoproteins | Drug discovery | Index Medicus
Journal Article
Journal Article
Journal Article
Journal Article
Lipids in health and disease, ISSN 1476-511X, 2017, Volume 16, Issue 1, pp. 1 - 17
The current review article is an attempt to explain the therapeutic potential of mangiferin, a bioactive compound of the mango, against lifestyle-related disorders. Mangiferin... 
Bioactive molecules | Nutrition | Toxicity | Health claims | Mangiferin | Human cancers | OXIDATIVE STRESS | LIPID-PEROXIDATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | MYELOID-LEUKEMIA CELLS | LUNG CARCINOGENESIS | BREAST-CANCER CELLS | IN-VITRO | NUTRITION & DIETETICS | STREPTOZOTOCIN-DIABETIC RATS | SWISS ALBINO MICE | INDICA L. EXTRACT | NF-KAPPA-B | Mangifera - chemistry | Antioxidants - chemistry | Cardiovascular Diseases - drug therapy | Humans | Neuralgia - pathology | Cardiovascular Diseases - pathology | Anti-Inflammatory Agents - therapeutic use | Anti-Inflammatory Agents - isolation & purification | Antineoplastic Agents, Phytogenic - therapeutic use | Cognitive Dysfunction - drug therapy | Hypoglycemic Agents - therapeutic use | Xanthones - chemistry | Xanthones - therapeutic use | Xanthones - isolation & purification | Hyperlipidemias - drug therapy | Nootropic Agents - isolation & purification | Nootropic Agents - therapeutic use | Antineoplastic Agents, Phytogenic - chemistry | Hypoglycemic Agents - chemistry | Cognitive Dysfunction - pathology | Nootropic Agents - chemistry | Neuralgia - drug therapy | Neoplasms - drug therapy | Hypoglycemic Agents - isolation & purification | Antioxidants - therapeutic use | Anti-Inflammatory Agents - chemistry | Antioxidants - isolation & purification | Hyperlipidemias - pathology | Diabetes Mellitus, Type 2 - pathology | Oxidative Stress - drug effects | Diabetes Mellitus, Type 2 - drug therapy | Neoplasms - pathology | Antineoplastic Agents, Phytogenic - isolation & purification | Dehydrogenases | Transcription | Lipid peroxidation | Lipids | Iron | Glucose | Matrix metalloproteinase | Kinases | Macrophages | Metastases | Antioxidants | β-catenin | Mitochondria | Enzymatic activity | Bioactive compounds | Rodents | Cell cycle | Antibacterial activity | Metalloproteinase | Gram-negative bacteria | Colon | Enzymes | Free radicals | Immunomodulation | Diabetes mellitus | Tumor necrosis factor-α | Metabolism | Nitric-oxide synthase | Flavonoids | Monocytes | Nitric oxide | Isoforms | Cancer | Matrilysin | Apoptosis
Journal Article
Metabolism, ISSN 0026-0495, 2017, Volume 69, pp. S3 - S7
Abstract Access to the CNS and delivery of therapeutics across the blood brain barrier remains a challenge for most treatments of major neurological diseases such as AD or PD... 
Endocrinology & Metabolism | Transcranial | Microbubbles | Transcalvarial FUS | Obicodilation | Sonothrombolysis | DRUG-DELIVERY | ALPHA-SYNUCLEIN | FUTURE | MODEL | BLOOD-BRAIN-BARRIER | IMMUNOTHERAPY | IN-VIVO | ENDOCRINOLOGY & METABOLISM | ALBUMIN | PARKINSONS-DISEASE | Neuroprotective Agents - therapeutic use | Parkinson Disease - therapy | Mechanical Thrombolysis - trends | Humans | Parkinson Disease - drug therapy | Neurodegenerative Diseases - drug therapy | Gene Transfer Techniques - adverse effects | Contrast Media - adverse effects | Therapies, Investigational - trends | Contrast Media - therapeutic use | Parkinson Disease - metabolism | Neuroprotective Agents - adverse effects | Neuroprotective Agents - administration & dosage | Ultrasonic Therapy - adverse effects | Alzheimer Disease - therapy | Mechanical Thrombolysis - adverse effects | Alzheimer Disease - drug therapy | Gene Transfer Techniques - trends | Microbubbles - adverse effects | Nootropic Agents - therapeutic use | Terminology as Topic | Neurodegenerative Diseases - therapy | Neurodegenerative Diseases - metabolism | Nootropic Agents - adverse effects | Microbubbles - therapeutic use | Mechanical Thrombolysis - methods | Ultrasonic Therapy - trends | Animals | Therapies, Investigational - adverse effects | Nootropic Agents - administration & dosage | Alzheimer Disease - metabolism | Stem Cell Transplantation - trends | Drug Delivery Systems - adverse effects | Blood-Brain Barrier | Stem Cell Transplantation - adverse effects | Usage | Therapeutics | Nervous system | Genetic engineering | Diagnostic imaging | Degeneration | Health aspects | Homeopathy | Materia medica and therapeutics | Prevention | electroencephalography | sonothrombolysis | microbubbles | MRI | transcranial | Aβ antibodies | neurotrophic factors (NTF) | obicodilation | β-amyloid plaque | transcalvarial FUS
Journal Article
British journal of nutrition, ISSN 0007-1145, 01/2015, Volume 113, Issue 2, pp. 350 - 365
Common pharmacological treatments of mood disorders aim to modulate serotonergic neurotransmission and enhance serotonin levels in the brain. Brain serotonin... 
Behaviour, Appetite and Obesity | Full Papers | Well-being | Serotonin | LumiVida | Tryptophan | Depression | Cognition | Emotion | FEMALE VOLUNTEERS | PLASMA TRYPTOPHAN | COGNITIVE PERFORMANCE | DEPRESSED-PATIENTS | HEALTHY-SUBJECTS | LumiVida (TM) | ALPHA-LACTALBUMIN INCREASES | NEUTRAL AMINO-ACIDS | VULNERABLE SUBJECTS | NUTRITION & DIETETICS | MOOD | Protein Hydrolysates - metabolism | Stress, Psychological - prevention & control | Nootropic Agents - metabolism | Humans | Middle Aged | Reaction Time | Antidepressive Agents - metabolism | Tryptophan - metabolism | Cognitive Dysfunction - prevention & control | Mental Fatigue - metabolism | Sleep Wake Disorders - metabolism | Depression - metabolism | Egg Proteins, Dietary - adverse effects | Psychiatric Status Rating Scales | Mental Fatigue - prevention & control | Tryptophan - blood | Stress, Psychological - metabolism | Egg Proteins, Dietary - therapeutic use | Female | Dietary Supplements - adverse effects | Beverages | Egg Proteins, Dietary - metabolism | Antidepressive Agents - blood | Serotonin Agents - therapeutic use | Protein Hydrolysates - therapeutic use | Double-Blind Method | Stress, Psychological - blood | Cognitive Dysfunction - metabolism | Nootropic Agents - therapeutic use | Cognitive Dysfunction - blood | Nootropic Agents - blood | Nootropic Agents - adverse effects | Protein Hydrolysates - adverse effects | Serotonin Agents - metabolism | Serotonin Agents - adverse effects | Antidepressive Agents - therapeutic use | Mental Fatigue - blood | Depression - prevention & control | Energy Metabolism | Sleep Wake Disorders - blood | Sleep Wake Disorders - prevention & control | Tryptophan - adverse effects | Aged | Serotonin Agents - blood | Antidepressive Agents - adverse effects | Tryptophan - therapeutic use | Cohort Studies | Depression - blood | Amino acids | Emotional disorders | Cognition & reasoning | Dietary supplements
Journal Article
The American journal of clinical nutrition, ISSN 1938-3207, 2015, Volume 101, Issue 3, pp. 538 - 548
Background: Recent evidence has indicated that flavanol consumption may have many health benefits in humans, including improved cognitive activities.... 
Lipid peroxidation | Insulin resistance | Cocoa flavanols | Blood pressure | Cognitive function | cognitive function | blood pressure | PROANTHOCYANIDINS | cocoa flavanols | PERFORMANCE | CHOCOLATE | FLAVAN-3-OLS | RICH COCOA | lipid peroxidation | IMPAIRMENT | CARDIOVASCULAR HEALTH | NUTRITION & DIETETICS | MOOD | INSULIN-RESISTANCE | insulin resistance | BRAIN | Beverages - adverse effects | Flavonols - adverse effects | Follow-Up Studies | Humans | Antihypertensive Agents - administration & dosage | Flavonols - therapeutic use | Hypertension - drug therapy | Male | Cognition | Cognitive Dysfunction - prevention & control | Cacao - adverse effects | Aged, 80 and over | Aging | Female | Flavonols - administration & dosage | Hypertension - diet therapy | Double-Blind Method | Dairy Products - adverse effects | Cognitive Dysfunction - metabolism | Insulin Resistance | Nootropic Agents - therapeutic use | Combined Modality Therapy | Antihypertensive Agents - therapeutic use | Cacao - chemistry | Nootropic Agents - adverse effects | Antihypertensive Agents - adverse effects | Hypertension - metabolism | Antioxidants - therapeutic use | Nootropic Agents - administration & dosage | Antioxidants - administration & dosage | Antioxidants - adverse effects | Aged | Lipid Peroxidation | Cohort Studies | Analysis | Beverages | Cocoa | Medical research | Flavonoids | Flavones | Bioflavonoids | Nutritional aspects | Medicine, Experimental | Research | Health aspects
Journal Article